Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bivalent enterovirus vaccine EV71 + CA16
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The bivalent enterovirus vaccine EV71 + CA16 is an inactivated biologic vaccine developed by Sinovac Biotech for the prevention of hand, foot and mouth disease (HFMD). It is designed to elicit a protective immune response against two of the most common causative agents of HFMD: Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16). By incorporating inactivated forms of both viruses, the vaccine aims to provide broader protection than existing monovalent EV71 vaccines. Sinovac received regulatory approval to begin clinical trials in China in July 2023 and initiated Phase I studies in September 2023, targeting infants and young children who are most susceptible to the disease.
- Other names
- bivalent enterovirus vaccine EV71 + CA16inactivated bivalent enterovirus vaccine (EV71 and CA16)Sinovac bivalent HFMD vaccine
02
Targets
Enterovirus A71 capsid proteinCoxsackievirus A16 virion/capsid antigens
Beyond the preview
Go deeper on bivalent enterovirus vaccine EV71 + CA16.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bivalent enterovirus vaccine EV71 + CA16.